Journal profile · Multiple
Blood Cancer Discovery
ISSN 2643-3230 · eISSN 2643-3249 · NLM (Medline)
Blood Cancer Discovery: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); hybrid open access; median 183 days to acceptance (80 articles, last 24 months); 71 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Blood Cancer Discovery is published by NLM (Medline) and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment and CAR-T cell therapy research, together about 37.8% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Research area (LetPub): Multiple
Main research topics OpenAlex counts of recent articles; shares are approximate
- Acute Myeloid Leukemia ResearchMedicine13%
- Lymphoma Diagnosis and TreatmentMedicine12.4%
- CAR-T cell therapy researchMedicine12.4%
- Protein Degradation and InhibitorsBiochemistry, Genetics and Molecular Biology7.3%
- Chronic Lymphocytic Leukemia ResearchMedicine6.1%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.5%
- Multiple Myeloma Research and TreatmentsMedicine5.2%
- Acute Lymphoblastic Leukemia researchMedicine4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
| Minor | Hematology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 13.9LetPub ·
- SJR 2026-06
- 4.62LetPub ·
- SNIP 2026-06
- 1.66LetPub ·
- h-index
- 46OpenAlex ·
- i10-index
- 154OpenAlex ·
- 2-year mean citedness
- 2.8OpenAlex ·
- Self-citation rate
- 2.5%LetPub ·
- Share of gold OA articles
- 41.46%LetPub ·
Volume
- Articles per year
- 33LetPub ·
Articles by year OpenAlex count · 721 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 138 | 23 | 25 |
| 2025 | 71 | 54 | 334 |
| 2024 | 123 | 46 | 572 |
| 2023 | 100 | 46 | 988 |
| 2022 | 92 | 53 | 1,267 |
| 2021 | 62 | 61 | 2,820 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
183 daysMedian, submission to acceptance · P25–P75 118 days – 239 days
- Acceptance to online
- median 4 days (15 articles)
- Submission to online
- median 175 days
- Sample
- 80 articles with submission and acceptance dates (144 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- NLM (Medline)
- ISSN
- 2643-3230
- Electronic ISSN
- 2643-3249
- Official links
- Journal homepage ↗OpenAlex
FAQ
Frequently asked questions about Blood Cancer Discovery
What CAS zone is Blood Cancer Discovery in?
In the 2025 upgraded edition of the CAS Journal Ranking, Blood Cancer Discovery is in Zone 1 of Medicine, and in Zone 1 of the minor category Hematology / Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Blood Cancer Discovery?
Based on the dates recorded on 80 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 183 days (interquartile range 118–239 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Blood Cancer Discovery?
According to LetPub and DOAJ records, Blood Cancer Discovery is indexed in ESCI and Scopus.
Is Blood Cancer Discovery open access, and what is the APC?
Blood Cancer Discovery is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .